These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 31539596)

  • 1. A long-acting, dual-agonist analogue of lamprey GLP-1 shows potent insulinotropic, β-cell protective, and anorexic activities and improves glucose homeostasis in high fat-fed mice.
    Graham GV; McCloskey A; Abdel-Wahab YH; Conlon JM; Flatt PR
    Mol Cell Endocrinol; 2020 Jan; 499():110584. PubMed ID: 31539596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucagon from the phylogenetically ancient paddlefish provides a template for the design of a long-acting peptide with effective anti-diabetic and anti-obesity activities.
    Graham GV; Conlon JM; Abdel-Wahab YH; Flatt PR
    Eur J Pharmacol; 2020 Jul; 878():173101. PubMed ID: 32320703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual-agonist incretin peptides from fish with potential for obesity-related Type 2 diabetes therapy - A review.
    Conlon JM; O'Harte FPM; Flatt PR
    Peptides; 2022 Jan; 147():170706. PubMed ID: 34861327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucagon-like peptides-1 from phylogenetically ancient fish show potent anti-diabetic activities by acting as dual GLP1R and GCGR agonists.
    Graham GV; Conlon JM; Abdel-Wahab YH; Flatt PR
    Mol Cell Endocrinol; 2019 Jan; 480():54-64. PubMed ID: 30312651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucagon-related peptides from phylogenetically ancient fish reveal new approaches to the development of dual GCGR and GLP1R agonists for type 2 diabetes therapy.
    Graham GV; Conlon JM; Abdel-Wahab YH; Flatt PR
    Peptides; 2018 Dec; 110():19-29. PubMed ID: 30391422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel dual incretin agonist peptide with antidiabetic and neuroprotective potential.
    Pathak NM; Pathak V; Gault VA; McClean S; Irwin N; Flatt PR
    Biochem Pharmacol; 2018 Sep; 155():264-274. PubMed ID: 30028989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice.
    Maida A; Hansotia T; Longuet C; Seino Y; Drucker DJ
    Gastroenterology; 2009 Dec; 137(6):2146-57. PubMed ID: 19766644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice.
    Green BD; Lavery KS; Irwin N; O'harte FP; Harriott P; Greer B; Bailey CJ; Flatt PR
    J Pharmacol Exp Ther; 2006 Aug; 318(2):914-21. PubMed ID: 16648370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates.
    Henderson SJ; Konkar A; Hornigold DC; Trevaskis JL; Jackson R; Fritsch Fredin M; Jansson-Löfmark R; Naylor J; Rossi A; Bednarek MA; Bhagroo N; Salari H; Will S; Oldham S; Hansen G; Feigh M; Klein T; Grimsby J; Maguire S; Jermutus L; Rondinone CM; Coghlan MP
    Diabetes Obes Metab; 2016 Dec; 18(12):1176-1190. PubMed ID: 27377054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel DPP IV-resistant C-terminally extended glucagon analogue exhibits weight-lowering and diabetes-protective effects in high-fat-fed mice mediated through glucagon and GLP-1 receptor activation.
    Lynch AM; Pathak N; Pathak V; O'Harte FP; Flatt PR; Irwin N; Gault VA
    Diabetologia; 2014 Sep; 57(9):1927-36. PubMed ID: 24962667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice.
    Bhat VK; Kerr BD; Vasu S; Flatt PR; Gault VA
    Diabetologia; 2013 Jun; 56(6):1417-24. PubMed ID: 23503814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the insulinotropic and glucose-lowering actions of zebrafish GIP in mammalian systems: Evidence for involvement of the GLP-1 receptor.
    Graham GV; Conlon JM; Abdel-Wahab YH; Gault VA; Flatt PR
    Peptides; 2018 Feb; 100():182-189. PubMed ID: 29157578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stapled, Long-Acting Xenopus GLP-1-Based Dual GLP-1/Glucagon Receptor Agonists with Potent Therapeutic Efficacy for Metabolic Disease.
    Han C; Sun Y; Yang Q; Zhou F; Chen X; Wu L; Sun L; Han J
    Mol Pharm; 2021 Aug; 18(8):2906-2923. PubMed ID: 34240881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological characterization and antidiabetic activity of a long-acting glucagon-like peptide-1 analogue conjugated to an antithrombin III-binding pentasaccharide.
    Patterson S; de Kort M; Irwin N; Moffett RC; Dokter WH; Bos ES; Miltenburg AM; Flatt PR
    Diabetes Obes Metab; 2015 Aug; 17(8):760-70. PubMed ID: 25929155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apelin-13 analogues show potent in vitro and in vivo insulinotropic and glucose lowering actions.
    O'Harte FPM; Parthsarathy V; Hogg C; Flatt PR
    Peptides; 2018 Feb; 100():219-228. PubMed ID: 29412822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The frog skin host-defense peptide CPF-SE1 improves glucose tolerance, insulin sensitivity and islet function and decreases plasma lipids in high-fat fed mice.
    Srinivasan D; Ojo OO; Owolabi BO; Conlon JM; Flatt PR; Abdel-Wahab YHA
    Eur J Pharmacol; 2015 Oct; 764():38-47. PubMed ID: 26123844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel glucagon-like peptide-1 (GLP-1)/glucagon hybrid peptide with triple-acting agonist activity at glucose-dependent insulinotropic polypeptide, GLP-1, and glucagon receptors and therapeutic potential in high fat-fed mice.
    Gault VA; Bhat VK; Irwin N; Flatt PR
    J Biol Chem; 2013 Dec; 288(49):35581-91. PubMed ID: 24165127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel GLP-1/xenin hybrid peptide improves glucose homeostasis, circulating lipids and restores GIP sensitivity in high fat fed mice.
    Hasib A; Ng MT; Khan D; Gault VA; Flatt PR; Irwin N
    Peptides; 2018 Feb; 100():202-211. PubMed ID: 29412820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. (Val(8))GLP-1-Glu-PAL: a GLP-1 agonist that improves hippocampal neurogenesis, glucose homeostasis, and β-cell function in high-fat-fed mice.
    Lennox R; Porter DW; Flatt PR; Gault VA
    ChemMedChem; 2013 Apr; 8(4):595-602. PubMed ID: 23138973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucoregulatory, endocrine and morphological effects of [P5K]hymenochirin-1B in mice with diet-induced glucose intolerance and insulin resistance.
    Owolabi BO; Ojo OO; Srinivasan DK; Conlon JM; Flatt PR; Abdel-Wahab YH
    Naunyn Schmiedebergs Arch Pharmacol; 2016 Jul; 389(7):769-81. PubMed ID: 27068334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.